

APPROVED DRUG PRODUCTS With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 01 January 2010



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

30th EDITION

Department of Health and Human Services

Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

30th EDITION

Cumulative Supplement 01

January 2010

CONTENTS

PAGE

1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vi
1.6 Cumulative Supplement Legend	
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.	
Orphan Product Designations and Approvals List	
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

30th EDITION

CUMULATIVE SUPPLEMENT 01 January 2010

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 29th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List. New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at <u>drugproducts@fda.hhs.gov</u>. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff Office of Generic Drugs, HFD-610 7500 Standish Place Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME	NEW APPLICANT NAME
(FORMER ABBREVIATED NAME)	(NEW ABBREVIATED NAME)
GOLDLINE LABORATORIES INC	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
(GOLDLINE)	(IVAX SUB TEVA PHARMS)
HLR TECHNOLOGY	HOFFMANN LA ROCHE INC
(HLR)	(HOFFMANN LA ROCHE)
IVAX PHARMACEUTICALS INC	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
(IVAX PHARMS)	(IVAX SUB TEVA PHARMS)
TEVA PHARMACEUTICALS USA	IVAX PHARMACEUTICALS INC SUB
	TEVA PHARMACEUTICALS USA
(TEVA PHARMS)	(IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE LABORATORIES INC	IVAX PHARMACEUTICALS INC SUB
	TEVA PHARMACEUTICALS USA
(ZENITH GOLDLINE)	(IVAX SUB TEVA PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS	IVAX PHARMACEUTICALS INC SUB
(ZENITH GOLDLINE)	TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARMS)

v

ZENITH GOLDLINE PHARMACEUTICALS INC

(ZENITH GOLDLINE)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at

http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 <u>REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST</u>

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2009	MAR 2010	JUN 2010	SEPT 2010	DEC 2010
DRUG PRODUCTS LISTED	13065				
SINGLE SOURCE	2460				
	(18.8%)				
MULTISOURCE	10516				
	(80.5%)				
THERAPEUTICALLY	10367				
EQUIVALENT	(79.3%)				
NOT THERAPEUTICALLY	149				
EQUIVALENT	(1.1%)				
EXCEPTIONS ¹	89				
	(0.7%)				
NEW MOLECULAR ENTITIES					
APPROVED	3				
NUMBER OF APPLICANTS	718				

 $^1\mathrm{Amino}$ acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to

the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A
	TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 30TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 1 - January 2010 1-1

		ACITRETIN								
		CAPSULE; ORAL SORIATANE								
>A>			17.5MG	N019821	003	Auq	06,	2009	Jan	NEWA
>A>			22.5MG	N019821		-				
							,			
		ALENDRONATE SODIUM								
		TABLET; ORAL								
		ALENDRONATE SODIUM								
>A>	AB	CADISTA PHARMS	EQ 5MG BASE	A090557	001	Feb	18,	2010	Jan	NEWA
>A>	AB		EQ 10MG BASE	A090557	002	Feb	18,	2010	Jan	NEWA
>A>	AB		EQ 35MG BASE	A090557	003	Feb	18,	2010	Jan	NEWA
>A>	AB		EQ 70MG BASE	A090557	004	Feb	18,	2010	Jan	NEWA
		AMLODIPINE BESYLATE; BENAZER	PRIL HYDROCHLORIDE							
		CAPSULE; ORAL								
			BENAZEPRIL HYDROCHLORIDE							
>A>	AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb	05,	2010	Jan	NEWA
>A>	AB		EQ 5MG BASE;10MG	A078466	002	Feb	05,	2010	Jan	NEWA
>A>	AB		EQ 5MG BASE;20MG	A078466	003	Feb	05,	2010	Jan	NEWA
>A>	AB		EQ 10MG BASE;20MG	A078466	004	Feb	05,	2010	Jan	NEWA
		AZELASTINE HYDROCHLORIDE								
		SPRAY, METERED; NASAL								
>D>		ASTELIN + MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114	0.01	Nov	01	1996	Jan	CTEC
>A>	AB	+	EQ 0.125MG BASE/SPRAY	N020111 N020114						
	112	AZELASTINE HYDROCHLORID			001	1.0.	01,	1990	0 dill	0120
>D>		@ APOTEX INC	- EQ 0.125MG BASE/SPRAY	A077954	001	Apr	30,	2009	Jan	CMFD
>A>	AB		EQ 0.125MG BASE/SPRAY	A077954		-				
		BACLOFEN								
		TABLET; ORAL BACLOFEN								
>A>	AB	MATRIX LABS LTD	10MG	A090334	001	Feb	18,	2010	Jan	NEWA
>A>	AB		20MG	A090334	002	Feb	18,	2010	Jan	NEWA
>D>		TABLET, ORALLY DISINTEGRAT	CING; ORAL							
>D>		KEMSTRO								
>D>		SCHWARZ PHARMA	10MG	N021589	001	Oct	30,	2003	Jan	DISC
>A>		@	10MG	N021589	001	Oct	30,	2003	Jan	DISC
>D>		+	20MG	N021589						
>A>		@	20MG	N021589	002	Oct	30,	2003	Jan	DISC
>D>		BETAXOLOL								
>D>		SOLUTION/DROPS; OPHTHALMIC								
>D>		BETAXOLOL								
>D>	AT	WOCKHARDT	EQ 0.5% BASE	A078694	001	Nov	16,	2009	Jan	CAIN
		BETAXOLOL HYDROCHLORIDE								
		SOLUTION/DROPS; OPHTHALMIC								
>D>		BETAXOLOL								
>D>	AT	AKORN	EQ 0.5% BASE	A075386	001	Jun	30,	2000	Jan	CTNA
>D>	AT	NOVEX	EQ 0.5% BASE	A075446	001	Sep	28,	2000	Jan	CTNA

		SOLUTION/DROPS; OPHTHALMIC								
>A>		BETAXOLOL HYDROCHLORIDE								
>A>	AT	AKORN	EQ 0.5% BASE	A075386						
>A>	AT	NOVEX	EQ 0.5% BASE	A075446		_				
>A>	AT	WOCKHARDT	EQ 0.5% BASE	A078694	001	Nov	16,	2009	Jan	CAIN
		SODIUM CITRATE	CHLORIDE; POTASSIUM CHLORIDE; SODI	UM ACETA	TE; S	SODIU	м Сн	LORID	<u>E;</u>	
		SOLUTION; IRRIGATION BALANCED SALT								
>A>	AT	B BRAUN	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9M G/ML;6.4MG/ML;1.7MG/ML	A091387	001	Feb	03,	2010	Jan	NEWA
		CEFADROXIL/CEFADROXIL HEMIHY	YDRATE							
		FOR SUSPENSION; ORAL								
		CEFADROXIL								
>D>	AB	LUPIN	EQ 500MG BASE/5ML	A065396	002	Feb	21.	2008	Jan	CRLD
	AB	+	EQ 500MG BASE/5ML	A065396						
>D>		DURICEF	- <u>x</u> · · · · · · · · · · · · · · · · · · ·				,			
>D>	AB	WARNER CHILCOTT	EO 250MG BASE/5ML	N050527	003				Jan	DISC
>A>		@	EQ 250MG BASE/5ML	N050527					Jan	DISC
>D>	AB	+	EQ 500MG BASE/5ML	N050527					Jan	DISC
>A>		@	EQ 500MG BASE/5ML	N050527	001				Jan	DISC
		CEFOTAXIME SODIUM								
		INJECTABLE; INJECTION								
		CEROENVINE CODIUM								
		CEFOTAXIME SODIUM								
>A>	AP	CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan	25,	2010	Jan	NEWA
>A>	AP	CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan	25,	2010	Jan	NEWA
>A>	AP	CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan	25,	2010	Jan	NEWA
>A>	AP	CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL		A065348	001	Jan	25,	2010	Jan	NEWA
>A> >A>	AP	CEPHAZONE PHARMA	E	A065348 A078617						
		CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORID	E							
		CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORID	E							
		CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORID: ACTAVIS MID ATLANTIC	E							
		CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC <u>CICLOPIROX</u>	E	A078617	001	Feb	02,	2010	Jan	NEWA
	AA	CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC <u>CICLOPIROX</u> SHAMPOO; TOPICAL CICLOPIROX	E		001	Feb	02,	2010	Jan	NEWA
>A>	AA	CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC <u>CICLOPIROX</u> SHAMPOO; TOPICAL CICLOPIROX	e 5MG/5ML	A078617	001	Feb	02,	2010	Jan	NEWA
>A>	AA	CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC <u>CICLOPIROX</u> SHAMPOO; TOPICAL CICLOPIROX PERRIGO	e 5MG/5ML	A078617	001	Feb	02,	2010	Jan	NEWA
>A>	AA AT	CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC <u>CICLOPIROX</u> SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL	e 5MG/5ML	A078617	001	Feb	02, 16,	2010 2010	Jan Jan	NEWA
>A> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDI ACTAVIS MID ATLANTIC CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX	E 5MG/5ML 1%	A078617 A078594	001	Feb	02, 16,	2010 2010	Jan Jan	NEWA
>A> >A>	AA AT	CEPHAZONE PHARMA <u>CETIRIZINE HYDROCHLORIDE</u> SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC <u>CICLOPIROX</u> SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM	E 5MG/5ML 1%	A078617 A078594	001	Feb	02, 16,	2010 2010	Jan Jan	NEWA
>A> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC CICLOPIROX SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN	E 5MG/5ML 1%	A078617 A078594	001	Feb	02, 16,	2010 2010	Jan Jan	NEWA
>A> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC CICLOPIROX SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN SPRAY, METERED; NASAL	E 5MG/5ML 1%	A078617 A078594	001 001 001	Feb Feb	02, 16, 17,	2010 2010 2010	Jan Jan	NEWA NEWA
>A> >A> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDI ACTAVIS MID ATLANTIC CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN SPRAY, METERED; NASAL CALOMIST	E 5MG/5ML 1% 8%	A078617 A078594 A078975	001 001 001	Feb Feb Jul	02, 16, 17, 27,	2010 2010 2010 2010	Jan Jan Jan	NEWA NEWA DISC
>A> >A> >A> >D> >D> >D> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC CICLOPIROX SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN SPRAY, METERED; NASAL CALOMIST + FLEMING @	E 5MG/5ML 1% 8% 25MCG/SPRAY	A078617 A078594 A078975 N022102	001 001 001	Feb Feb Jul	02, 16, 17, 27,	2010 2010 2010 2010	Jan Jan Jan	NEWA NEWA DISC
>A> >A> >A> >A> >D> >D> >D> >D> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC CICLOPIROX SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN SPRAY, METERED; NASAL CALOMIST + FLEMING @ DALFAMPRIDINE	E 5MG/5ML 1% 8% 25MCG/SPRAY 25MCG/SPRAY	A078617 A078594 A078975 N022102	001 001 001	Feb Feb Jul	02, 16, 17, 27,	2010 2010 2010 2010	Jan Jan Jan	NEWA NEWA DISC
>A> >A> >A> >D> >D> >D> >D> >D> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC CICLOPIROX SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN SPRAY, METERED; NASAL CALOMIST + FLEMING @ DALFAMPRIDINE TABLET, EXTENDED RELEASE;	E 5MG/5ML 1% 8% 25MCG/SPRAY 25MCG/SPRAY	A078617 A078594 A078975 N022102	001 001 001	Feb Feb Jul	02, 16, 17, 27,	2010 2010 2010 2010	Jan Jan Jan	NEWA NEWA DISC
>A> >A> >A> >A> >D> >D> >D> >D> >A>	AA AT	CEPHAZONE PHARMA CETIRIZINE HYDROCHLORIDE SYRUP; ORAL CETIRIZINE HYDROCHLORIDE ACTAVIS MID ATLANTIC CICLOPIROX SHAMPOO; TOPICAL CICLOPIROX PERRIGO SOLUTION; TOPICAL CICLOPIROX VERSAPHARM CYANOCOBALAMIN SPRAY, METERED; NASAL CALOMIST + FLEMING @ DALFAMPRIDINE	E 5MG/5ML 1% 8% 25MCG/SPRAY 25MCG/SPRAY	A078617 A078594 A078975 N022102	001 001 001 001	Feb Feb Jul Jul	02, 16, 17, 27, 27,	2010 2010 2010 2007 2007	Jan Jan Jan Jan	NEWA NEWA DISC DISC

		DESLORATADINE							
		TABLET; ORAL							
		CLARINEX							
>D>	AB	+ SCHERING PLOUGH	5MG 5MG	N021165					
>A> >A>	АВ	+ DESLORATADINE	SIMG	N021165	UUI	Dec 2.	L, 2001	Uall	CFIG
>A>	AB	ORCHID HLTHCARE	5MG	A078357	001	Feb 1	9, 2010	Jan	NEWA
		DESMOPRESSIN ACETATE							
		SPRAY, METERED; NASAL							
>D>		STIMATE (NEEDS NO REFRIC		N020355	000	0 = 1 0	1 2005	Tem	DIGG
>A>		@ CSL BEHRING	1.5MG/SPRAY	NU2U355	002	UCL 24	±, 2007	Jan	DISC
>D>		DEXMEDETOMIDINE							
>D>		INJECTABLE; INJECTION							
>D>		PRECEDEX	EO 100MCC DACE/MI	NO 01 0 2 0	0.01	Dog 1	7 1000	Tan	CATN
>D>		+ HOSPIRA	EQ 100MCG BASE/ML	N021038	001	Dec I	/, 1999	Jan	CAIN
>A>		DEXMEDETOMIDINE HYDROCHLORII	DE						
>A>		INJECTABLE; INJECTION							
>A>		PRECEDEX	EO 100MGG DAGE /ML (EO100MGG	NTO 01 0 2 0	0.01	Dec. 1	7 1000	Tem	CATN
>A>		+ HOSPIRA	EQ 100MCG BASE/ML (EQ100MCG BASE/ML	NUZIU38	001	Dec I	7, 1999	Jan	CAIN
		DICLOFENAC POTASSIUM							
		TABLET; ORAL							
_		DICLOFENAC POTASSIUM	5.0.42		0.01	- 1 0	0001	-	DIAG
>D> >A>	AB	SANDOZ @	50MG 50MG	A075582 A075582					
		<u> </u>		110 / 00 01	001	100 2	, 2001	oun	2100
		EPINEPHRINE							
		INJECTABLE; IM-SC							
		TWINJECT 0.15			0.0.0	Mar. 0		T	ann
>D> >A>		+ SCIELE PHARMA INC + SHIONOGI PHARMA	EQ 0.15MG /DELIVERY EQ 0.15MG /DELIVERY	N020800 N020800		-			
~~~		TWINJECT 0.3	EQ 0.15MG / DELIVERT	1020000	002	May 20	5, 2001	Uall	CAIN
>D>		+ SCIELE PHARMA INC	EQ 0.3MG /DELIVERY	N020800	001	May 3	), 2003	Jan	CAHN
>A>		+ SHIONOGI PHARMA	EQ 0.3MG /DELIVERY	N020800	001	May 3	), 2003	Jan	CAHN
		ESTRADIOL VALERATE							
		INJECTABLE; INJECTION							
		ESTRADIOL VALERATE							
>A>	AO	PHARMAFORCE	20MG/ML	A090920					
>A>	AO		40MG/ML	A090920	002	Jan 1	9, 2010	Jan	NEWA
		ETHINYL ESTRADIOL; NORETHINE	DRONE						
		TABLET; ORAL-28							
	_	NORETHINDRONE AND ETHINY						_	
>A>	AB	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG 0.035MG:0.4MG	A076393					
~ ~ ~	ΔR			AU 78392	(11)1	H-00 0.	<u>. 2010</u>	Jan	N H W A

>A> AB WATSON LABS A078323 001 Feb 04, 2010 Jan NEWA >A> AB 0.035MG;0.4MG

>A> >A> >A> >A>	AB		ND ETHINYL ESTRADIOL AND FERROUS 0.02MG;1MG	5 FUMARATE A078267	001	Sep	01,	2009	Jan	CDFR
>D>		NORETHINDRONE ACETATE A	ND ETHINYL ESTRADIOL AND FERROUS	5 FUMARATE						
>D>	AB	WATSON LABS	0.02MG;1MG	A078267	001	Sep	01,	2009	Jan	CDFR
	FAM	OTIDINE								
>D>	Tž	ABLET, ORALLY DISINTEGRA	FING; ORAL							
>D>		FLUXID								
>D>		SCHWARZ PHARMA	20MG	N021712	001	Sep	24,	2004	Jan	DISC
>A>		@	20MG	N021712	001	Sep	24,	2004	Jan	DISC
>D>	+		40MG	N021712	002	Sep	24,	2004	Jan	DISC
>A>		@	40MG	N021712	002	Sep	24,	2004	Jan	DISC
		DFIBRATE APSULE; ORAL ANTARA (MICRONIZED)								
>A>		LUPIN ATLANTIS	43MG	N021695	001	Nov	30,	2004	Jan	CAHN
>A>		@	87MG	N021695	002	Nov	30,	2004	Jan	CAHN
>A>	+		130MG	N021695	003	Nov	30,	2004	Jan	CAHN
>D>		OSCIENT	43MG	N021695	001	Nov	30,	2004	Jan	CAHN
>D>		@	87MG	N021695	002	Nov	30,	2004	Jan	CAHN
>D>	+		130MG	N021695	003	Nov	30,	2004	Jan	CAHN
	Τž	ABLET; ORAL								
		FENOGLIDE								
>D>		SCIELE PHARMA INC	40MG	N022118		5	,			
>D>	+		120MG	N022118		-				
>A>		SHIONOGI PHARMA	40MG	N022118		-				
>A>	+		120MG	N022118	002	Aug	10,	2007	Jan	CAHN

#### FLUCONAZOLE

	INJECTABLE; INJECTION						
>A>	FLUCONAZOLE IN SODIU	M CHLORIDE 0.9%					
>A>	BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26,	2008 Jan	CTNA
>D>	FLUCONAZOLE IN SODIU	M CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	BEDFORD	100MG/50ML (2MG/ML)	A076087	002	Sep 26,	2008 Jan	CTNA

FOLIC ACID

		TABLET; ORAL		
		FOLIC ACID		
>D>	AA	PHARMAX	1MG	A040625 001 Jul 21, 2005 Jan CRLD
>A>	AA	+	1MG	A040625 001 Jul 21, 2005 Jan CRLD
>D>		@ WATSON LABS	1MG	A080680 001 Jan CMFD
>A>	AA	+	1MG	A080680 001 Jan CMFD

#### GLYBURIDE; METFORMIN HYDROCHLORIDE

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

		TABLET; ORAL			
		GLYBURIDE AND	METFORMIN HYDROCHLORIDE		
>D>	AB	TEVA	1.25MG;250MG	A076821 001 Jan 27, 2005 Jan DISC	1
>A>		@	1.25MG;250MG	A076821 001 Jan 27, 2005 Jan DISC	!
>D>	AB		2.5MG;500MG	A076821 002 Jan 27, 2005 Jan DISC	!
>A>		@	2.5MG;500MG	A076821 002 Jan 27, 2005 Jan DISC	!
>D>	AB		5MG;500MG	A076821 003 Jan 27, 2005 Jan DISC	!

		TABLET; ORAL								
		GLYBURIDE AND METFORMIN	HYDROCHLORIDE							
>A>		@ TEVA	5MG;500MG	A076821	003	Jan	27,	2005	Jan	DISC
		GLYCOPYRROLATE								
		TABLET; ORAL								
		ROBINUL								
>D>	AA	+ SCIELE PHARMA INC	1MG	N012827	001				Jan	CAHN
>A>	AA	+ SHIONOGI PHARMA	1MG	N012827	001				Jan	CAHN
		ROBINUL FORTE								
>D>	AA	+ SCIELE PHARMA INC	2MG	N012827	002				Jan	CAHN
>A>	AA	+ SHIONOGI PHARMA	2MG	N012827	002				Jan	CAHN
		HYDRALAZINE HYDROCHLORIDE								
		TABLET; ORAL								
		HYDRALAZINE HYDROCHLORII	DE							
>A>	AA	HERITAGE PHARMS INC	10MG	A086242	001	Feb	04,	2010	Jan	NEWA
>A>	AA		100MG	A086242	004	Feb	04,	2010	Jan	NEWA
		HYDROCHLOROTHIAZIDE								
		CAPSULE; ORAL								
		HYDROCHLOROTHIAZIDE								
>A>	AB	UNICHEM	12.5MG	A090510	001	Jan	19,	2010	Jan	NEWA
		HYDROCHLOROTHIAZIDE; LISINOPRIL								
		TABLET; ORAL LISINOPRIL AND HYDROCHLO								
>D>	AB	TEVA	12.5MG;10MG	A075869	0.01		01	2002	Tan	DISC
>A>	лD	@	12.5MG/10MG	A075869						
	תא		12.5MG/10MG	A075869						
>D>	AB									
>A>		@	12.5MG;20MG	A075869						
>D>	AB		25MG; 20MG	A075869						
>A>		@	25MG;20MG	A075869	003	Jul	0Ι,	2002	Jan	DISC
		HYDROCHLOROTHIAZIDE; METOPRO	DLOL TARTRATE							
		TABLET; ORAL								
		METOPROLOL TARTRATE AND	HYDROCHLOROTHIAZIDE							
>D>	AB	MYLAN	25MG;100MG	A076792	002	Aug	20,	2004	Jan	CRLD
>A>	AB	+	25MG;100MG	A076792						
>D>	AB		50MG;100MG	A076792		-				
>A>			50MG;100MG	A076792						
							- /			
		IBUPROFEN								
		TABLET; ORAL								
		IBUPROFEN								
>A>	AB	CONTRACT PHARMACAL	400MG	A071267	001	Oct	15,	1986	Jan	CAHN
>A>	AB		600MG	A071268						
>A>	AB		800MG	A072300						
>D>	AB	LEINER	400MG	A071267						
>D>	AB		600MG	A071268						
>D>	AB		800MG	A072300						
-			-				/			
		IFOSFAMIDE								
		INJECTABLE; INJECTION								

IFOSFAMIDE

>D> AP + APP PHARMS 1GM/VIAL

A076078 001 May 28, 2002 Jan CTEC

		INJECTABLE; INJECTION								
		IFOSFAMIDE								
>A>		+ APP PHARMS	1GM/VIAL	A076078	001	May	28,	2002	Jan	CTEC
>D>	AP		1GM/VIAL	A090181	001	Sep	22,	2009	Jan	CPOT
>A>	AP		1GM/20ML (50MG/ML)	A090181	001	Sep	22,	2009	Jan	CPOT
>D>	AP	+	3GM/VIAL	A076078	002	May	28,	2002	Jan	CTEC
>A>		+	3GM/VIAL	A076078	002	May	28,	2002	Jan	CTEC
>D>	AP		3GM/VIAL	A090181	002	Sep	22,	2009	Jan	CPOT
>A>	AP		3GM/60ML (50MG/ML)	A090181	002	Sep	22,	2009	Jan	CPOT
>D>		+ TEVA PARENTERAL	1GM/20ML (50MG/ML)	A076657	001	Apr	04,	2007	Jan	CTEC
>A>	AP	+	1GM/20ML (50MG/ML)	A076657	001	Apr	04,	2007	Jan	CTEC
>D>		+	3GM/60ML (50MG/ML)	A076657	002	Apr	04,	2007	Jan	CTEC
>A>	AP	+	3GM/60ML (50MG/ML)	A076657	002	Apr	04,	2007	Jan	CTEC
		LABETALOL HYDROCHLORIDE								
		INJECTABLE; INJECTION LABETALOL HYDROCLORIDE								
>A>	AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb	03.	2010	Jan	NEWA
- 11-	111			11079191	001	100	05,	2010	oun	1111111
		LENALIDOMIDE								
		CAPSULE; ORAL								
		REVLIMID								
>D>		CELGENE	5MG	N021880	001	Dec	27,	2005	Jan	CRLD
>A>		+	5MG	N021880						
		ΙΕΊΙΕΥΙΟΛΟΓΊΑΜ								
		LEVETIRACETAM								
		TABLET; ORAL								
		LEVETIRACETAM	25.040	3070060	0.0.4	<b>T</b> - 1-	0.1	0010	<b>T</b>	
>A>	AB	TARO	250MG	A078960						
>A>	AB		500MG	A078960						
>A>	AB		750MG	A078960						
>A>	AB		lGM	A078960	001	rep	UΙ,	2010	Jan	NEWA
>A>		LIRAGLUTIDE RECOMBINANT								
>A>		SOLUTION; SUBCUTANEOUS								
>A>		VICTOZA								
>A>		+ NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan	25,	2010	Jan	NEWA
		LISINOPRIL								
		TABLET; ORAL								
		LISINOPRIL								
>D>	AB	TEVA	2.5MG	A075783	001	Jul	01,	2002	Jan	DISC
>A>		@	2.5MG	A075783	001	Jul	01,	2002	Jan	DISC
>D>	AB		5MG	A075783	002	Jul	01,	2002	Jan	DISC
>A>		@	5MG	A075783	002	Jul	01,	2002	Jan	DISC
>D>	AB		10MG	A075783	003	Jul	01,	2002	Jan	DISC
>A>		@	10MG	A075783	003	Jul	01,	2002	Jan	DISC
>D>	AB		20MG	A075783	004	Jul	01,	2002	Jan	DISC
>A>		@	20MG	A075783	004	Jul	01,	2002	Jan	DISC
>D>	AB		30MG	A075783	005	Jul	01,	2002	Jan	DISC
>A>		@	30MG	A075783	005	Jul	01,	2002	Jan	DISC
>D>	AB		40MG	A075783	006	Jul	01,	2002	Jan	DISC
>A>		@	40MG	A075783	006	Jul	01,	2002	Jan	DISC

		LITHIUM CARBONATE							
		CAPSULE; ORAL							
>D>		ESKALITH							
>D>	AB	NOVEN THERAP	300MG	N016860	001			Jan	DISC
>A>		@	300MG	N016860	001			Jan	DISC
		MECLIZINE HYDROCHLORIDE							
		TABLET; ORAL							
		ANTIVERT							
>D>		@ PFIZER	50MG	N010721	001	Jan 20	, 1982	Jan	CMFD
>A>	AA	+	50MG	N010721	001	Jan 20	, 1982	Jan	CMFD
>D>		TABLET, CHEWABLE; ORAL							
>D>		ANTIVERT							
>D>		+ PFIZER	25MG	N010721	005			Jan	DISC
>A>		@	25MG	N010721	005			Jan	DISC
		METFORMIN HYDROCHLORIDE							
		TABLET, EXTENDED RELEASE; METFORMIN HYDROCHLORIDE	ORAL						
>A>	AB	TORRENT PHARMS	750MG	A079226	001	Feb 18	, 2010	Jan	NEWA
		METOCLOPRAMIDE HYDROCHLORIDE	<u>-</u>						
		TABLET; ORAL							
		METOCLOPRAMIDE HYDROCHLO	ORIDE						
>D>	AB	SANDOZ	EQ 10MG BASE	A074478	002	Oct 05	, 1995	Jan	DISC
>A>		@	EQ 10MG BASE	A074478	002	Oct 05	, 1995	Jan	DISC
>D>	AB	WATSON LABS	EQ 10MG BASE	A070511	001	Jan 22	, 1986	Jan	DISC
>A>		@	EQ 10MG BASE	A070511	001	Jan 22	, 1986	Jan	DISC
		MILRINONE LACTATE							
		INJECTABLE; INJECTION							
		MILRINONE LACTATE IN PLA							
>A>	AP	HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)						
>A>	AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038	002	Jan 21	, 2010	Jan	NEWA
		MORPHINE SULFATE							
		SOLUTION; ORAL							
		MORPHINE SULFATE							
>D>		+ ROXANE	20MG/5ML	N022195	002	Mar 17	, 2008	Jan	CRLD
>A>			20MG/5ML	N022195	002	Mar 17	, 2008	Jan	CRLD
>A>		+	100MG/5ML	N022195	003	Jan 25	, 2010	Jan	NEWA
		NISOLDIPINE							
		TABLET, EXTENDED RELEASE; SULAR	ORAL						
>D>		+ SCIELE PHARMA INC	8.5MG	N020356	008	Jan 02	, 2008	Jan	CAHN
>D>		@	10MG	N020356	001	Feb 02	, 1995	Jan	CAHN
>D>		+	17MG	N020356	007	Jan 02	, 2008	Jan	CAHN
>D>		@	20MG	N020356	002	Feb 02	, 1995	Jan	CAHN
>D>			25.5MG	N020356					CAHN
>D>		@	30MG	N020356					CAHN
>D>		+	3 4MG	N020356					CAHN
>D>		@	40MG	N020356	004	гер 02	, 1995 ,	Jan	CAHN

		TABLET, EXTENDED RELEASE	; ORAL						
>A>		SULAR + SHIONOGI PHARMA	8.5MG	N020356	008	Jan 0	2 2008	Jan	CAHN
>A>		@	10MG	N020356					
>A>		+	17MG	N020356					
>A>		@	20MG	N020356					
>A>		-	25.5MG	N020356					
>A>		@	30MG	N020356					
>A>		+	34MG	N020356					
>A>		@	40MG	N020356	004	Feb 0	2, 1995	Jan	CAHN
		NITROFURANTOIN							
		SUSPENSION; ORAL							
		FURADANTIN							
>D>		+ SCIELE PHARMA INC	25MG/5ML	N009175	001			Jan	CAHN
>A>		+ SHIONOGI PHARMA	25MG/5ML	N009175	001			Jan	CAHN
		NITROGLYCERIN							
		AEROSOL; SUBLINGUAL							
		NITROLINGUAL							
>D>		@ POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 3	L, 1985	Jan	CAHN
>A>		@ SHIONOGI PHARMA	0.4MG/SPRAY	N018705	001	Oct 3	L, 1985	Jan	CAHN
		SPRAY, METERED; SUBLINGU NITROLINGUAL PUMPSPRAY	AL						
>D>		+ POHL BOSKAMP	0.4MG/SPRAY	N018705	002	Jan 1	), 1997	Jan	CAHN
>A>		+ SHIONOGI PHARMA	0.4MG/SPRAY	N018705	002	Jan 1	), 1997	Jan	CAHN
		OFLOXACIN							
		TABLET; ORAL							
		OFLOXACIN							
>A>		@ LARKEN LABS	200MG	A076093	001	Sep 0	2, 2003	Jan	CAHN
>A>		@	300MG	A076093	002	Sep 0	2, 2003	Jan	CAHN
>A>		@	400MG	A076093	003	Sep 0	2, 2003	Jan	CAHN
>D>		@ PAR PHARM	200MG	A076093	001	Sep 0	2, 2003	Jan	CAHN
>D>		@	300MG	A076093	002	Sep 0	2, 2003	Jan	CAHN
>D>		@	400MG	A076093	003	Sep 0	2, 2003	Jan	CAHN
		OXALIPLATIN							
		INJECTABLE; INJECTION							
		OXALIPLATIN							
>D>	AP	HOSPIRA INC	50MG/VIAL	A078815	001	Sep 3	), 2009	Jan	CRLD
>A>	AP	+	50MG/VIAL	A078815	001	Sep 3	), 2009	Jan	CRLD
>D>	AP		100MG/VIAL	A078815	002	Sep 3	), 2009	Jan	CRLD
>A>	AP	+	100MG/VIAL	A078815	002	Sep 3	), 2009	Jan	CRLD
		OXCARBAZEPINE							
		TABLET; ORAL							
		OXCARBAZEPINE							
>A>	AB	CADISTA PHARMS	150MG	A090239					
>A>	AB		300MG	A090239					
>A>	AB		600MG	A090239	003	Jan 2	5, 2010	Jan	NEWA

PALIPERIDONE PALMITATE

>D>

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR INVEGA SUSTENNA

JOHNSON AND JOHNSON 234MG/1.5ML (156MG/ML)

```
N022264 005 Jul 31, 2009 Jan CRLD
```

		SUSPENSION, EXTENDED RELEA	ASE; INTRAMUSCULAR							
>A>		INVEGA SUSTENNA + JOHNSON AND JOHNSON	234MG/1.5ML (156MG/ML)	N022264	005	Jul	31,	2009	Jan	CRLD
		PERINDOPRIL ERBUMINE								
		TABLET; ORAL								
		PERINDOPRIL ERBUMINE								
>A>	AB	LUPIN LTD	2MG	A078263						
>A> >A>	AB AB		4MG	A078263						
>A>	АБ		8MG	A078263	003	Uall	27,	2010	Jan	NEWA
		POLYETHYLENE GLYCOL 3350; PC SULFATE ANHYDROUS	DTASSIUM CHLORIDE; SODIUM BICARBONA	TE; SODI	UM CH	HLORI	DE ;	SODIU	<u>M</u>	
		FOR SOLUTION; ORAL								
>A>	AA	PEG 3350 AND ELECTROLYTI MYLAN	236GM;2.97GM;6.74GM;5.86GM;22.74G	7000020	0.01	Tan	20	2010	Top	NEWA
~A>	AA	MILLAN	M	A090928	001	Uall	20,	2010	Uall	INEWA
		PRAZOSIN HYDROCHLORIDE								
		CAPSULE; ORAL								
		PRAZOSIN HYDROCHLORIDE								
>D>	AB	WATSON LABS	EQ 1MG BASE	A072352	001	Мау	16,	1989	Jan	DISC
>A>		@	EQ 1MG BASE	A072352		-				
>D>	AB		EQ 2MG BASE	A072333		-				
>A>		@	EQ 2MG BASE	A072333	001	мау	16,	1989	Jan	DISC
		PREDNISONE								
		TABLET; ORAL								
>A>	AB	PREDNISONE CONTRACT PHARMACAL	5MG	A080209	0.01				Ton	CAHN
>D>	AB AB	LEINER	5MG 5MG	A080209						CAHN
101	110		5110	11000209	001				oun	Crant
		PREGABALIN								
>A>		SOLUTION; ORAL								
>A>		LYRICA	20MG /MT	N022488	0.01	Tam	0.4	2010	Tem	NTEL17
>A>		+ PFIZER	20MG/ML	NU22488	001	Jan	04,	2010	Jan	NEWA
>D>		PROCAINE HYDROCHLORIDE								
>D>		INJECTABLE; INJECTION								
>D>		PROCAINE HYDROCHLORIDE								
>D> >A>		+ WATSON LABS @	1%	A080658 A080658						DISC DISC
~~~		<b></b>	Τ.0	A000050	001				Uall	DISC
		PROCHLORPERAZINE MALEATE								
. D.		TABLET; ORAL	_							
>D> >D>	AB	PROCHLORPERAZINE MALEATI		A040268	001	Feb	27	1008	Jan	CTINA
>D>	AB AB	CADISTA PHARMS	EQ 5MG BASE EQ 10MG BASE	A040268						
>D>	AB	DURAMED PHARMS BARR	EQ 5MG BASE	A040207						
>A>		@	EQ 5MG BASE	A040207		-				
>D>	AB		EQ 10MG BASE	A040207	002	May	01,	1997	Jan	DISC
>A>		@	EQ 10MG BASE	A040207	002	May	01,	1997	Jan	DISC
>A>		PROCOMP								
>A>	AB	CADISTA PHARMS	EQ 5MG BASE	A040268						
>A>	AB		EQ 10MG BASE	A040268	002	Feb	27,	1998	Jan	CTNA

		PROPOXYPHENE HYDROCHLORIDE								
		CAPSULE; ORAL								
		PROPOXYPHENE HYDROCHLOR	IDE							
>D>	AA	PAR PHARM	65MG	A080269	001				Jan	DISC
>A>		@	65MG	A080269	001				Jan	DISC
		QUINIDINE SULFATE								
		TABLET; ORAL								
		QUINIDINE SULFATE								
>A>		@ CONTRACT PHARMACAL	200MG	A083808	001				Jan	CAHN
>D>		@ LEINER	200MG	A083808	001				Jan	CAHN
		RISPERIDONE								
		INJECTABLE; INTRAMUSCULAR								
		RISPERDAL CONSTA								
>D>		ORTHO MCNEIL JANSSEN	25MG/VIAL	N021346	001	Oct	29,	2003	Jan	CRLD
>A>		+	25MG/VIAL	N021346	001	Oct	29,	2003	Jan	CRLD
>D>		+	50MG/VIAL	N021346	003	Oct	29,	2003	Jan	CRLD
>A>			50MG/VIAL	N021346	003	Oct	29,	2003	Jan	CRLD
		SULFAMETHOXAZOLE; TRIMETHOPP	RIM							
		TABLET; ORAL								
		SULFAMETHOXAZOLE AND TR	IMETHOPRIM							
>A>	AB	AUROBINDO PHARMA	400MG;80MG	A090624	001	Feb	16,	2010	Jan	NEWA
>A>	AB		800MG;160MG	A090624	002	Feb	16,	2010	Jan	NEWA
		TERCONAZOLE								
		CREAM; VAGINAL TERCONAZOLE								
>D>	вх	+ ALTANA	0.8%	N021735	001	Oct.	01.	2004	Jan	CAHN
>A>	вх	+ NYCOMED US	0.8%	N021735						
		TOPIRAMATE								
		TABLET; ORAL TOPIRAMATE								
>D>	AB	PLIVA HRVATSKA DOO	25MG	A077905	001	Mar	30,	2009	Jan	DISC
>A>		@	25MG	A077905	001	Mar	30,	2009	Jan	DISC
>D>	AB		50MG	A077905	002	Mar	30,	2009	Jan	DISC
>A>		@	50MG	A077905	002	Mar	30,	2009	Jan	DISC
>D>	AB		100MG	A077905	003	Mar	30,	2009	Jan	DISC
>A>		@	100MG	A077905	003	Mar	30,	2009	Jan	DISC
>D>	AB		200MG	A077905	004	Mar	30,	2009	Jan	DISC
>A>		@	200MG	A077905	004	Mar	30,	2009	Jan	DISC
>D>		UNOPROSTONE ISOPROPYL								
>D>		SOLUTION/DROPS; OPHTHALMIC	2							
>D> >D>		RESCULA	0.15%	NTO 01 01 4	0.01	۸۰۰~	02	2000	Tom	DICC
>D> >A>		+ R TECH UENO LTD @ SUCAMPO PHARMS	0.15%	N021214 N021214						
		TIRCODIOI								
		URSODIOL								
		CAPSULE; ORAL								

URSODIOL >A> AB MYLAN 300MG VALPROATE SODIUM

INJECTABLE; INJECTION

 VALPROATE SODIUM

 >A> AP
 HIKMA FARMACEUTICA
 EQ 100MG BASE/ML
 A078523 001 Feb 17, 2010 Jan NEWA

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 1 - January 2010 2-1

	CETIRIZINE HYDROCHLORIDE								
	SYRUP; ORAL								
	CHILDREN'S CETIRIZINE	HYDROCHLORIDE ALLERGY							
>A>	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb	02,	2010	Jan	NEWA
	CHILDREN'S CETIRIZINE	HYDROCHLORIDE HIVES RELIEF							
>A>	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb	02,	2010	Jan	NEWA
	TABLET; ORAL								
	CETIRIZINE HYDROCHLORI	DE ALLERGY							
>A>	AMNEAL PHARMS NY	5MG	A078780						
>A>		10MG	A078780	004	Jan	21,	2010	Jan	NEWA
	CETIRIZINE HYDROCHLORI								
>A>	AMNEAL PHARMS NY	5MG	A078780						
>A>		10MG	A078780	002	Jan	21,	2010	Jan	NEWA
	CIMETIDINE								
	TABLET; ORAL CIMETIDINE								
>A>	CONTRACT PHARMACAL	200MG	A074961	001	Jun	19,	1998	Jan	CAHN
>A>		200MG	A074963						
>D>	LEINER	200MG	A074961						
>D>		200MG	A074963	001	Jun	19,	1998	Jan	CAHN
	IBUPROFEN								
	CAPSULE; ORAL								
>A>	IBUPROFEN + CONTRACT PHARMACAL	200MG	A074782	0.01	T., 1	06	1000	Top	CAUN
>D>	+ LEINER	200MG 200MG	A074782						
- 0-	TABLET; ORAL	200110	A071702	001	our	00,	1))0	oan	CAIN
	IBUPROFEN								
>A>	CONTRACT PHARMACAL	200MG	A071732	001	Sep	10.	1987	Jan	CAHN
>A>		200MG	A071735		-				
>A>		200MG	A072299		-				
>A>		200MG	A073691	001	Feb	25,	1994	Jan	CAHN
>D>	LEINER	200MG	A071732	001	Sep	10,	1987	Jan	CAHN
>D>		200MG	A071735	001	Sep	10,	1987	Jan	CAHN
>D>		200MG	A072299	001	Jul	01,	1988	Jan	CAHN
>D>		200MG	A073691	001	Feb	25,	1994	Jan	CAHN
	PROFEN								
>A>	CONTRACT PHARMACAL	200MG	A071265	001	Oct	15,	1986	Jan	CAHN
>D>	LEINER	200MG	A071265	001	Oct	15,	1986	Jan	CAHN
	IBUPROFEN; PSEUDOEPHEDRINE	HYDROCHLORIDE							
	TABLET; ORAL								
	IBUPROFEN AND PSEUDOEP	HEDRINE HYDROCHLORIDE							
>A>	CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr	08,	2002	Jan	CAHN
>D>	LEINER	200MG;30MG	A075588	001	Apr	08,	2002	Jan	CAHN
	LOPERAMIDE HYDROCHLORIDE								
	TABLET; ORAL								
	LOPERAMIDE HYDROCHLORI	DE							
> 2 >	CONTRACT DHARMACAL	2MC	2073254	001	.Tu1	30	1002	Tan	CAUM

>A>	CONTRACT PHARMACAL	2MG	A073254	001	Jul	30,	1993	Jan	CAHN
>D>	LEINER	2MG	A073254	001	Jul	30,	1993	Jan	CAHN

	MICONAZOLE NITRATE								
	CREAM; VAGINAL								
	MICONAZOLE NITRATE								
>A>	PERRIGO R AND D	4%	A091366	001	Jan	15,	2010	Jan	NEWA
	NAPHAZOLINE HYDROCHLORIDE;	PHENIRAMINE MALEATE							
	SOLUTION/DROPS; OPHTHALMI	c							
	VISINE-A								
>D>	JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan	31,	1996	Jan	CRLD
>A>	+	0.025%;0.3%	N020485	001	Jan	31,	1996	Jan	CRLD
	RANITIDINE HYDROCHLORIDE								
	TABLET; ORAL								
	RANITIDINE HYDROCHLORID	E							
>A>	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun	21,	1999	Jan	CAHN
>D>	LEINER	EQ 75MG BASE	A075094	001	Jun	21,	1999	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 01 JANUARY 2010

NO JANUARY 2010 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JANUARY 2010 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 1 - January 2010

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	E	PATI XPIRA DAT	ATION		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
	POLYETHYLENE GLY	COL 3	350;	POTASS	SIUM	CHLORIDE;	SODIUM ASCORE	ATE; SODIUM CHI	LORIDE; SODIUM
<u>SULFATE - MOVI</u> N021881 001	<u>PREP</u> > A> 7658914	Sep	01,	2024	DS	DP			
BALSALAZIDE DIS	SODIUM - COLAZAL								
N020610 001	> A> 7452872	Aug	24,	2026		U-141			
	>A> 7452872*PED	Feb	24,	2027					
	> A> 7625884	-		2026		U-141			
	> A> 7625884*PED	Feb	24,	2027					
BUDESONIDE - RI	HINOCORT								
N020746 001	> A> 6686346	Apr	29,	2017		DP U-557	Y		
	>A> 6686346*PED	Oct	29,	2017					
	> A> 6986904	Apr	29,	2017		DP U-699	Y		
	> A> 6986904*PED	Oct	29,	2017					
BUDESONIDE - RI	HINOCORT								
N020746 002	> A > 6686346	Apr	29,	2017		DP U-557			
	>A> 6686346*PED	- Oct	29,	2017					
	> A> 6986904	Apr	29,	2017		DP U-699			
	>A> 6986904*PED	Oct	29,	2017					
DIDDODION UVDD	OBROMIDE - APLENZ	TN							
N022108 001	>A> 7645802		27	2026		DP			
1022100 001	>A> 7649019			2026		DP			
			,						
	OBROMIDE - APLENZ								
N022108 002	> A > 7645802	Jun		2026		DP			
	>A> 7649019	Jun	27,	2026		DP			
BUPROPION HYDRO	OBROMIDE - APLENZ	IN							
N022108 003	> A> 7645802	Jun	27,	2026		DP			
	> A> 7649019	Jun	27,	2026		DP			
CAPSAICIN - QU	TENZA								
N022395 001								>A> ODE	Nov 16, 2016
CEFTIBUTEN DIH	ערקעע – אייעמעע								
N050686 001	>A> 5599557	Feb	04.	2014		DP U-578			
1050000 001	>A> 5599557			2014		DP U-282			
			/						
CEFTIBUTEN DIHY									
N050686 002	> A > 5599557			2014		DP U-578			
	>A> 5599557	Feb	04,	2014		DP U-282			
CLONIDINE HYDRO	OCHLORIDE - JENLO	GA							
N022331 001	> A> 5869100	Oct	13,	2013		DP			
DALFAMPRIDINE	- AMPYRA								
N022250 001								>A> NCE	Jan 22, 2015
DICLOFENAC POTA	ASSIUM - ZIPSOR								
N022202 001	> A> 6365180	Jul	15,	2019		DP U-980			
DULOXETINE HYDI	ROCHLORIDE - CYMB	ALTA							
N021427 003	>A> 5023269	Jun	11,	2013	DS	DP U-797			
	> A> 5508276	Jul		2014		DP			

A - 1

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	EXP	PATENT PIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)		LUSI PIRA DAT	
EZETIMIBE - ZE										
N021445 001			25, 2022 25, 2022		U-1027					
TNSULTN GLULTS	INE RECOMBINANT -	APTDRA	A SOLOSTAF	2						
N021629 003			18, 2018	-	DP U-471					
0005	>A> 6960561		25, 2023		DP U-471					
	> A > 7452860		22, 2022		DP					
LAMOTRIGINE -	LAMICTAL XR									
N022115 001							>A> NDF	-		2012
							> A> PED	Nov	29,	2012
LAMOTRIGINE -	LAMICTAL XR									
N022115 002							>A> NDF >A> PED	-		2012 2012
LAMOTRIGINE -	LAMICTAL XR									
N022115 003							>A> NDF	May	29,	2012
							>A> PED	Nov	29,	2012
LAMOTRIGINE -	LAMICTAL XR									
N022115 004							> A> NDF > A> PED	-		2012 2012
							PED	NOV	29,	2012
N022059 001	SYLATE - TYKERB						> A > I-620	Tan	20	2013
							XX 1-020	Uall	29,	2013
LEVETIRACETAM	- KEPPRA						NAN T EGO	Mox	10	2010
N021872 001							> A> I-563 > A> PED			2010 2010
LIRAGLUTIDE RE	COMBINANT - VICTO	ZA								
	> A> 6268343		22, 2017	DS	DP U-968		>A> NCE	Jan	25,	2015
	> A> 6458924	Aug	22, 2017	DS	DP					
	> A> 7235627	Aug	22, 2017	DS	DP					
LISDEXAMFETAMI	NE DIMESYLATE - V	YVANSE								
N021977 001	> A> 7655630	Feb	24, 2023	DS						
I.TSDEXAMFETAMT	NE DIMESYLATE - V	YVANSE								
	>A> 7655630		24, 2023	DS						
TTODEVAMEEMAMT										
N021977 003	<u>NE DIMESYLATE - V</u> >A> 7655630		24, 2023	DS						
			21, 2025	DB						
	NE DIMESYLATE - V		24 2022	Da						
N021977 004	> A > 7655630	гер .	24, 2023	DS						
	NE DIMESYLATE - V									
N021977 005	> A> 7655630	Feb	24, 2023	DS						
LISDEXAMFETAMI	NE DIMESYLATE - V	YVANSE								
N021977 006	> A> 7655630	Feb	24, 2023	DS						
MESALAMINE - S	FROWASA									
N019618 002	> A> 7645801	Jul 2	24, 2027	DS	DP					
PANTOPRAZOLE S	ODIUM - PROTONIX									
N022020 001	>A> 7544370	Jun	07, 2026		DP					
001	>A> 7544370*PED		07, 2026							

See List footnote for information regarding List content

PATENT PATENT EXCLU EXPIRATION PATENT DELIST EXCLUSIVITY EXPIN NO PATENT NO DATE CODES REQUESTED CODE(S) DA									
PRAMIPEXOLE DI	HYDROCHLORIDE - P	RAMIPEXC	LE DIHYI	DROCHLORIDE					
A077724 001						> A> PC	Jul	03, 2010	
PRAMIPEXOLE DI	HYDROCHLORIDE - P	PRAMIPEXC	LE DIHYI	DROCHLORIDE					
A077724 002						> A> PC	Jul	03, 2010	
PRAMIPEXOLE DI	HYDROCHLORIDE - P	PRAMIPEXC	LE DIHYI	DROCHLORIDE					
A077724 003						> A> PC	Jul	03, 2010	
PRAMIPEXOLE DI	IHYDROCHLORIDE - F	RAMIPEXC	LE DIHYI	DROCHLORIDE					
A077724 004						> A> PC	Jul	03, 2010	
PRAMIPEXOLE DI	IHYDROCHLORIDE - P	RAMIPEXC	LE DIHYI	DROCHLORIDE					
A077724 005						> A> PC	Jul	03, 2010	
PREGABALIN - I	JYRICA								
N022488 001	>A> 5563175	Oct 08	8, 2013	U-661		> A> I-535	Jun	21, 2010	
	>A> 6001876	Dec 30	, 2018	U-819					
	>A> 6001876	Dec 30	, 2018	U-55					
	> A> 6197819	Dec 30), 2018	DS DP					
REGADENOSON -	LEXISCAN								
N022161 001	> A> 7655636	Jun 22	2, 2019	U-869					
	> A> 7655637	Jun 22	2, 2019	DS DP U-869					
ROMIDEPSIN - I	ISTODAX								
N022393 001						>A> ODE	Nov	05, 2016	
TIOTROPIUM BRO	MIDE MONOHYDRATE	- SPIRIV	A						
N021395 001	> A> 7642268	Sep 24	, 2021	DS DP					
TOLTERODINE TA	ARTRATE - DETROL								
N020771 001	>A> 5559269	Nov 05	, 2013	U-318	Y				
	>A> 5559269*PED	May 05	5, 2014						
TOLTERODINE TA	ARTRATE – DETROL								
N020771 002		Nov 05	5, 2013	U-318	Y				
	> A> 5559269*PED	May 05							

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the <u>APPROVED DRUG</u> <u>PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS</u>, 30th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm